Sharp, a leading provider of pharmaceutical packaging and clinical services, has strengthened its clinical leadership team with the appointment of Robert Feltz as Director, Analytical and Formulation Services and Michael MacNeir as Vice President, Global Business Development.
Robert Feltz has over 15 years of industry experience and moves to Sharp from Altasciences where he was Director of Analytical Services with responsibility for method validation, stability, and release testing. He also oversaw multiple drug candidates from pre-clinical to commercial launch. Robert holds a Bachelor of Science degree in Chemistry from Shepherd University and a Master of Science degree in Chemistry from Pennsylvania State University.
Michael MacNeir joins Sharp from Marken where he was VP of Commercial Operations for the Americas. He brings over 14 years of clinical trial supply and operational experience, as well as a strong track record of success in commercial growth strategies. Michael has a particular interest in Direct-to-Patient and decentralised clinical trials. He holds a BA in Psychology from Stockton University.
Commenting on the appointments, Managing Director of Sharp Clinical Robert O’Beirn said:
“I am delighted to welcome Robert Feltz and Michael MacNeir to Sharp and I am confident they will make a significant contribution in shaping and growing our clinical business. Their respective industry expertise will put us in a stronger position to deliver and expand our client-led clinical solutions, to better serve our customers and their patients.”
These new appointments follow the recent news that Sharp Clinical has formed a strategic partnership with ClinsChain to expand its reach into the Chinese market. The company has also recently completed an expansion of its clinical service offering from its European facility in Heerenveen, The Netherlands.